Drug Information

Drug General Information
Drug ID
D0R7JT
Former ID
DAP001105
Drug Name
Fludrocortisone
Synonyms
Alflorone; Astonin; FCOL; Florinef; Fludrocortisona; Fludrocortisonum; Fludrocortone; Fludrone; Fludronef; Fluodrocortisone; Fluohydrisone; Fluohydrocortisone; Fluorocortisol; Fluorocortisone; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; StC 1400; U 5963; ZK5; Astonin-H; F-COL; F-Cortef;Florinef (TN); Fludrocortisona [INN-Spanish]; Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Fludrocortisonum [INN-Latin]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 .alpha. FF; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha FF; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11.beta.,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-Fluorocortisol; 9-Fluorohydrocortisone; 9-alpha-Fludrocortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorocortisol; 9-alpha-Fluorohydrocortisone; 9.alpha.-Fluoro-11.beta.,17.alpha.,21-trihydroxy-4-pregnene-3,20-dione; 9.alpha.-Fluoro-17-hydroxycorticosterone; 9.alpha.-Fluorocortisol; 9.alpha.-Fluorohydrocortisone; 9alpha-Fludrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluoro-hydrocortisone; 9alpha-Fluorocortisol
Drug Type
Small molecular drug
Indication Cerebral salt-wasting syndrome [ICD10:E87.1] Approved [538426], [539899]
Therapeutic Class
Antiinflammatory Agents
Structure
Download
2D MOL

3D MOL
Formula
C21H29FO5
InChI
InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
InChIKey
AAXVEMMRQDVLJB-BULBTXNYSA-N
CAS Number
CAS 127-31-1
PubChem Compound ID
31378
PubChem Substance ID
9217, 76336, 7891224, 7979235, 8172141, 10321611, 15375738, 24702328, 34673521, 46508616, 46508716, 48416020, 50019673, 50125791, 50864760, 56352851, 57311202, 71831474, 85286070, 96024662, 104234355, 104310733, 117567350, 123059725, 126651363, 126687973, 127307282, 127379594, 134338350, 135269929, 135650268, 137003338, 139326855, 144080988, 144206253, 144206895, 160963328, 160964032, 162176728, 164841599, 170464959, 175266519, 179214416, 196108113, 196404089, 223657072, 226396521, 249910373
ChEBI ID
ChEBI:50885
SuperDrug ATC ID
H02AA02
SuperDrug CAS ID
cas=000127311
Target and Pathway
Target(s) Mineralocorticoid receptor Target Info Agonist [535856], [537575]
KEGG Pathway Aldosterone-regulated sodium reabsorption
PathWhiz Pathway Kidney Function
WikiPathways ACE Inhibitor Pathway
References
Ref 538426FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010060.
Ref 539899(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2873).
Ref 535856Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
Ref 537575Addison's disease. BMJ. 2009 Jul 2;339:b2385. doi: 10.1136/bmj.b2385.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.